Bruton's Tyrosine Kinase: A Potential Novel Target for Neurological Disorders
1Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. danica.michalickova@lf1.cuni.cz; Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. ondrej.slanar@lf1.cuni.cz.
Physiological Research
|May 28, 2025
Summary
Bruton's tyrosine kinase (BTK) plays a key role in brain inflammation and neurological diseases like Alzheimer's. Inhibiting BTK may offer a new therapeutic strategy for these conditions.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Bruton's tyrosine kinase (BTK) is integral to B-cell receptor signaling and has roles beyond cancer.
- Emerging research highlights BTK's involvement in neurological disorders and brain metabolism.
- Inflammasome activation, particularly NLRP3, is a key mechanism linking BTK to neuroinflammation.
Purpose of the Study:
- To explore the underappreciated roles of BTK in various brain diseases.
- To discuss the therapeutic potential of BTK inhibition for neurological conditions.
Main Methods:
- Literature review and synthesis of current research on BTK in neurological diseases.
- Analysis of the role of BTK in inflammasome activation and neuroinflammation.
Main Results:
- BTK is implicated in the pathophysiology of multiple sclerosis, Alzheimer's disease, and brain injury.
- BTK activation contributes to age-related and disease-associated neuroinflammation via inflammasomes.
- BTK inhibition presents a promising avenue for treating neurological disorders.
Conclusions:
- BTK is a significant factor in neurological disease pathogenesis.
- Targeting BTK offers a potential therapeutic strategy for a range of brain conditions.
More Related Videos
Related Concept Videos
01:00Enzyme-linked Receptors
77.5K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
01:26Receptor Tyrosine Kinases
12.4K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
12.4K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
00:49The Blood-brain Barrier
47.0K
Overview
47.0K
01:29Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K